<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03561311</url>
  </required_header>
  <id_info>
    <org_study_id>2017-NEAT-2</org_study_id>
    <nct_id>NCT03561311</nct_id>
  </id_info>
  <brief_title>The Neuroprotective Effect of Remote Ischemic Conditioning in Ruptured Aneurysm Coiling Therapy</brief_title>
  <acronym>NEAT-2</acronym>
  <official_title>The Neuroprotective Effect of Remote Ischemic Conditioning in Ruptured Aneurysm Coiling Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Capital Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Capital Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall incidence of DWI positive for thromboembolic events following endovascular
      treatment of intracranial aneurysms is proximately 50%. Whether remote ischemic conditioning
      was safe and effective to reduce ischemic brain lesions on DWI after endovascular treatment
      of intracranial aneurysms is still unclear. The investigators' hypothesis is that remote
      ischemic conditioning is a safe and effective strategy to reduce new ischemic lesions in
      intracranial aneurysms patients undergoing endovascular treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 6, 2018</start_date>
  <completion_date type="Anticipated">June 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The presence of ≥1 new brain lesions on DWI</measure>
    <time_frame>within 72 hours after endovascular treatment</time_frame>
    <description>Assessed by DWI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of new ischemic lesions</measure>
    <time_frame>within 72 hours after endovascular treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of new ischemic lesions</measure>
    <time_frame>within 72 hours after endovascular treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>National Institutes of Health Stroke Scale</measure>
    <time_frame>7 days or discharge</time_frame>
    <description>Scores on the National Institutes of Health Stroke Scale (NIHSS) range from 0 to 42, with higher scores indicating more severe neurologic deficits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of Cerebrovascular events</measure>
    <time_frame>30 days</time_frame>
    <description>This is a composited endpoint.Cerebrovascular events included ischemic stroke, hemorrhagic stroke, and TIA. The present subarachnoid hemorrhage isn't included.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nondisabling events</measure>
    <time_frame>30 days</time_frame>
    <description>Scores on the National Institutes of Health Stroke Scale (NIHSS) range from 0 to 42, with higher scores indicating more severe neurologic deficits.National Institutes of Health Stroke Scale ≤3 or TIA is defined as nondisabling events The present subarachnoid hemorrhage isn't included.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Rankin Scale</measure>
    <time_frame>30 days</time_frame>
    <description>Scores on the modified Rankin scale of functional disability range from 0 (no symptoms) to 6 (death).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Occurrence of adverse events and serious adverse events</measure>
    <time_frame>30 days</time_frame>
    <description>Occurrence of adverse events and serious adverse events</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">210</enrollment>
  <condition>Aneurysm, Ruptured</condition>
  <condition>Coiling Therapy</condition>
  <arm_group>
    <arm_group_label>Remote ischemic conditioning group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham remote ischemic conditioning group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>remote ischemic conditioning</intervention_name>
    <description>Remote ischemic conditioning is performed by using an electric autocontrol device with cuffs that inflated to a pressure of 200 mm Hg during the ischemic period (Patent No. CN200820123637.X, China)</description>
    <arm_group_label>Remote ischemic conditioning group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>sham remote ischemic conditioning</intervention_name>
    <description>Sham remote ischemic conditioning is performed by using an electric autocontrol device with cuffs that inflated to a pressure of 60 mm Hg</description>
    <arm_group_label>Sham remote ischemic conditioning group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 years or older

          -  Ruptured brain aneurysm deemed suitable for neuroendovascular repair

          -  Normal baseline brain MRI

          -  Female subjects of childbearing potential have a negative pregnancy test.

          -  Signed informed consent prior to entering study

        Exclusion Criteria:

          -  Dissecting or mycotic brain aneurysm.

          -  Planned endovascular vessel sacrifice as the primary modality for aneurysm treatment

          -  Renal insufficiency with creatinine ≥ 265 umol/L

          -  Severe, sustained hypertension (SBP &gt; 185 mmHg or DBP &gt; 110 mmHg)

          -  Contraindication for remote ischemic conditioning: severe soft tissue injury,
             fracture, or peripheral vascular disease in the upper limbs

          -  Pre-morbid modified Rankin scale score of greater than 1

          -  Patients with a pre-existing neurological or psychiatric disease that would confound
             the neurological or functional evaluations Patients who are unable to have an MRI scan
             for any reason.

          -  Currently participating or previously participated in any investigational drug or
             device study within 6 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xunming Ji, MD</last_name>
    <phone>008601083198930</phone>
    <email>jixm@ccmu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Xuanwu Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100053</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xunming Ji</last_name>
    </contact>
    <investigator>
      <last_name>Xunming Ji</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shengli Oilfield Central Hospital</name>
      <address>
        <city>Dongying</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zongen Gao</last_name>
    </contact>
    <investigator>
      <last_name>Zongen Gao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Second People's Hospital of Liaocheng</name>
      <address>
        <city>Liaocheng</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wansheng Chang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nanyang City Center Hospital</name>
      <address>
        <city>Nanyang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Changming Wen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Zhengzhou University</name>
      <address>
        <city>Zhengzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yajun Lian</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>May 23, 2018</study_first_submitted>
  <study_first_submitted_qc>June 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 19, 2018</study_first_posted>
  <last_update_submitted>November 21, 2018</last_update_submitted>
  <last_update_submitted_qc>November 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Capital Medical University</investigator_affiliation>
    <investigator_full_name>Ji Xunming,MD,PhD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Aneurysm, Ruptured</mesh_term>
    <mesh_term>Rupture</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

